Molecularly targeted treatment for dermatofibrosarcoma protuberans

Seminars in Oncology

Volumn 31, Issue SUPPL. 6, 2004, Pages 30-36

  McArthur, Grant ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR B; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

CHROMOSOME 17; CHROMOSOME 22; CHROMOSOME REARRANGEMENT; CLINICAL TRIAL; DERMATOFIBROSARCOMA PROTUBERANS; GENE FUSION; GENE TARGETING; HUMAN; IMMUNOBLOTTING; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; TISSUE PRESSURE; TUMOR GROWTH; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; METABOLISM; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; DERMATOFIBROSARCOMA; DRUG DELIVERY SYSTEMS; HUMANS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SKIN NEOPLASMS;

EID: 2942668235     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.03.038     Document Type: Article

References (36)

1. Gloster H.M. Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol. 35:1996;355-374. quiz 375-356
2. Bowne W.B., Antonescu C.R., Leung D.H., et al. Dermatofibrosarcoma protuberans A clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 88:2000;2711-2720
3. Simon M.P., Pedeutour F., Sirvent N., et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet. 15:1997;95-98
4. Shimizu A., O'Brien K.P., Sjöblom T., et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59:1999;3719-3723
5. Naeem R., Lux M.L., Huang S.F., et al. Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol. 147:1995;1553-1558
6. O'Brien K.P., Seroussi E., Dal Cin P., et al. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer. 23:1998;187-193
7. Wang J., Hisaoka M., Shimajiri S., et al. Detection of COL1A1-PDGFB fusion transcripts in dermatofibrosarcoma protuberans by reverse transcription-polymerase chain reaction using archival formalin-fixed, paraffin-embedded tissues. Diagn Mol Pathol. 8:1999;113-119
8. Sandberg A.A., Bridge J.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet. 140:2003;1-12
9. Gisselsson D., Hoglund M., O'Brien K.P., et al. A case of dermatofibrosarcoma protuberans with a ring chromosome 5 and a rearranged chromosome 22 containing amplified COL1A1 and PDGFB sequences. Cancer Lett. 133:1998;129-134
10. Sonobe H., Furihata M., Iwata J., et al. Dermatofibrosarcoma protuberans harboring t(9;22)(q32;q12.2). Cancer Genet Cytogenet. 110:1999;14-18
11. Sjöblom T., Shimizu A., O'Brien K.P., et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 61:2001;5778-5783
12. Sirvent N., Maire G., Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors From ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer. 37:2003;1-19
13. Greco A., Roccato E., Miranda C., et al. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer. 92:2001;354-360
14. Buchdunger E., O'Reilly T., Wood J. Pharmacology of imatinib (STI571). Eur J Cancer. 38:(suppl 5):2002;S28-S36
15. Maki R.G., Awan R.A., Dixon R.H., et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer. 100:2002;623-626
16. Rubin B.P., Schuetze S.M., Eary J.F., et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 20:2002;3586-3591
17. Labropoulos S., Papadopoulos S., Hadjiyiassemi L., et al. Response of metastatic dermatofibrosarcoma protuberans to imatinib mesylate. Proc Am Soc Clin Oncol. 22:2003;830. (abstr)
18. McArthur G., Demetri G., Heinrich M.C., et al. Molecular and clinical analysis of response to imatinib for locally advanced dermatofibrosarcoma protuberans. Proc Am Soc Clin Oncol. 22:2003;195. (abstr)
19. Mark R.J., Bailet J.W., Tran L.M., et al. Dermatofibrosarcoma protuberans of the head and neck. A report of 16 cases. Arch Otolaryngol Head Neck Surg. 119:1993;891-896
20. Rutgers E.J., Kroon B.B., Albus-Lutter C.E., et al. Dermatofibrosarcoma protuberans Treatment and prognosis. Eur J Surg Oncol. 18:1992;241-248
21. Brabant B., Revol M., Vergote T., et al. Dermatofibrosarcoma protuberans of the chest and the shoulder Wide and deep excisions with immediate reconstruction. Plast Reconstr Surg. 92:1993;459-462
22. Arnaud E.J., Perrault M., Revol M., et al. Surgical treatment of dermatofibrosarcoma protuberans. Plast Reconstr Surg. 100:1997;884-895
23. Mohs F.E. Chemosurgery. Clin Plast Surg. 7:1980;349-360
24. Gloster H.M. Jr, Harris K.R., Roenigk R.K. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol. 35:1996;82-87
25. Nouri K., Lodha R., Jimenez G., et al. Mohs micrographic surgery for dermatofibrosarcoma protuberans University of Miami and NYU experience. Dermatol Surg. 28:2002;1060-1064
26. Suit H., Spiro I., Mankin H.J., et al. Radiation in management of patients with dermatofibrosarcoma protuberans. J Clin Oncol. 14:1996;2365-2369
27. Ballo M.T., Zagars G.K., Pisters P., et al. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys. 40:1998;823-827
28. Sun L.M., Wang C.J., Huang C.C., et al. Dermatofibrosarcoma protuberans Treatment results of 35 cases. Radiother Oncol. 57:2000;175-181
29. Pietras K., Sjöblom T., Rubin K., et al. PDGF receptors as cancer drug targets. Cancer Cell. 3:2003;439-443
30. Savage D.G., Antman K.H. Imatinib mesylate-A new oral targeted therapy. N Engl J Med. 346:2002;683-693
31. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:1998;577-580
32. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:2003;708-710
33. Magnusson M.K., Meade K.E., Nakamura R., et al. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood. 100:2002;1088-1091
34. Apperley J.F., Gardembas M., Melo J.V., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 347:2002;481-487
35. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 348:2003;1201-1214
36. Corless C., Heinrich M., Dimitrijevic S., et al. Correlation of imatinib response with activation of KIT and PDGF receptors in a variety of cancers Results of the CSTIB2225 trial. Proc Am Soc Clin Oncol. 22:2003;195. (abstr)